Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trialThomas Powles, Felipe Reyes, Yohann Loriot et al.|The Lancet Oncology|2021Cited by 645
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell CarcinomaRana R. McKay, Toni K. Choueiri, Dominick Bossé et al.|Cancer Immunology Research|2018Cited by 136
Molecular characterization of metastatic penile squamous cell carcinoma in developing countries and its impact on clinical outcomes: LACOG 2018 translational studyFernando Sabino Marques Monteiro, André P. Fay|The Oncologist|2024Cited by 7
Table S1 from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaDavid J. Kwiatkowski, Sabina Signoretti, Toni K. Choueiri et al.|Unknown|2023Cited by 0
Table S1 from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaDavid J. Kwiatkowski, Sabina Signoretti, Toni K. Choueiri et al.|Unknown|2023Cited by 0